Innovative Bispecific Nanobody Targeting ADAMTS5 and ALB for Advanced Arthritis Therapy

VHH-P718 is a fully humanized bispecific nanobody that targets both ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5) and albumin (ALB). Currently in the Biological Testing development phase, VHH-P718 harnesses the complementary biological activities of these two elements, offering a novel approach with the potential to address a significant unmet need in the treatment of arthritis. By simultaneously engaging ADAMTS5 and ALB, VHH-P718 is designed to maximize therapeutic impact and bioavailability, establishing a promising foundation for clinical translation in arthritis management.

Licensing Opportunity

VHH-P718 is currently available for out-licensing. We welcome collaboration opportunities with industry partners to accelerate its clinical development and unlock its full commercial potential in arthritis treatment.

Development Phase

Modality

VHH-P718 is a bispecific nanobody composed of two single-domain antibodies targeting distinct proteins—ADAMTS5 and ALB. This nanobody format is characterized by its small molecular size, robust structural stability, and high tissue penetration, which can confer advantages in targeting inflamed joint tissues associated with arthritis. The humanized sequence design enhances immunogenic tolerance, while the bispecific nature allows for simultaneous modulation of pathogenic mechanisms and extension of systemic half-life. These structural attributes collectively support improved delivery and sustained action in the challenging microenvironment of arthritic tissues.

Target

ADAMTS5 is a metalloprotease involved in cartilage matrix degradation and is predominantly expressed in joint tissues, especially under arthritic conditions. ALB is the most abundant plasma protein, with roles in molecule transport and serum half-life extension. ADAMTS5 contributes directly to the degradation of cartilage proteoglycans in arthritis, making it an attractive target for disease modification. ALB, broadly present in the circulatory system, serves as a strategic partner for half-life extension of therapeutics. By targeting both ADAMTS5 and ALB, VHH-P718 aims to inhibit pathological cartilage breakdown while leveraging ALB binding to prolong systemic exposure. This dual strategy supports potent, long-lasting disease intervention in arthritis and positions VHH-P718 as a valuable asset in the competitive biotherapeutics landscape.

Mechanism of Action

VHH-P718 exerts its therapeutic effect via concurrent binding to ADAMTS5 and ALB. By selectively inhibiting ADAMTS5, VHH-P718 is designed to block the enzymatic activity responsible for cartilage breakdown in arthritic joints. The simultaneous engagement with ALB potentially enhances the molecule’s circulatory stability and systemic persistence, optimizing therapeutic dosing and exposure. As a bispecific nanobody, VHH-P718 embodies the modularity and adaptability characteristic of nanobody platforms, paving the way for further development into advanced biotherapeutic formats such as bispecifics with additional functionalities, or integration into antibody-drug conjugate (ADC) approaches.

Arthritis

Arthritis encompasses a heterogeneous group of inflammatory joint diseases, including osteoarthritis and various forms of inflammatory arthritis such as rheumatoid arthritis. This group of disorders is highly prevalent globally and represents a leading cause of pain and disability among adults. Mainstream therapies include nonsteroidal anti-inflammatory drugs, disease-modifying agents, biologics, and targeted therapies, each accompanied by distinct limitations such as partial efficacy, adverse effects, and resistance in subsets of patients. Despite available treatments, substantial unmet medical needs persist, especially regarding long-term disease modification, safety profile, and convenient administration. VHH-P718’s targeted approach—addressing both ADAMTS5-mediated cartilage degradation and half-life optimization via ALB—holds promise for achieving more effective, sustained disease control and improving quality of life for arthritis patients.